Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

GLP-1 receptor agonists work on GLP-1 receptors, which are located throughout your body, including in your brain and central nervous system, Varisco explains. “In the brain, GLP-1 receptors act ...

It’s not yet entirely clear why GLP-1 drugs help with addiction, but it may have to do with the overlap between the appetite circuits in the brain with the reward pathways involved in addiction ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...